Honeywell International Inc vs 22nd Century Group Inc — how do they compare? Honeywell International Inc trades at $232.42 (market cap $71.66B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Honeywell International Inc is far larger — about 48094× 22nd Century Group Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| HON | XXII | |
|---|---|---|
Market Cap | $71.66B | $1.49M |
Sector | Industrials | Technology |
52-Week High | $248.04 | $1.07K |
52-Week Low | $188.14 | $3.90 |
Enterprise Value | $96.01B | -$6.74M |
Dividend Yield | 4.21% | — |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $225.78, up 0.34% with a bullish technical signal and strong institutional support. The company maintains solid fundamentals with a 10.89% net margin and 26.41% ROE, though recent earnings show mixed trends with Q1 2026 beating expectations but full-year 2026 guidance indicating potential decline. Recent developments include the completion of a £1.325 billion acquisition and a 2:1 reverse stock split.
The outlook remains positive with analyst consensus favoring Buy ratings (65.52%) and a $368.55 price target representing significant upside. Key risks include execution challenges post-spinoffs and margin pressure, while opportunities lie in automation growth and strategic acquisitions. The stock presents a balanced risk-reward profile for long-term investors.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →